Sökning: onr:"swepub:oai:gup.ub.gu.se/335561" > Impact of BMI in Pa...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05921naa a2200937 4500 | |
001 | oai:gup.ub.gu.se/335561 | |
003 | SwePub | |
008 | 240910s2023 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:237556775 | |
009 | oai:prod.swepub.kib.ki.se:154966939 | |
024 | 7 | a https://gup.ub.gu.se/publication/3355612 URI |
024 | 7 | a https://doi.org/10.1200/JCO.23.001262 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2375567752 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1549669392 URI |
040 | a (SwePub)gud (SwePub)kid (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Pfeiler, Georg4 aut |
245 | 1 0 | a Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial |
264 | 1 | c 2023 |
520 | a PURPOSEBMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib.METHODSPatients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived.RESULTSOf 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months).CONCLUSIONThis preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome. This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Hlauschek, Dominik4 aut |
700 | 1 | a Mayer, Erica L.4 aut |
700 | 1 | a Deutschmann, Christine4 aut |
700 | 1 | a Kacerovsky-Strobl, Stephanie4 aut |
700 | 1 | a Martin, Miguel4 aut |
700 | 1 | a Meisel, Jane Lowe4 aut |
700 | 1 | a Zdenkowski, Nicholas4 aut |
700 | 1 | a Loibl, Sibylle4 aut |
700 | 1 | a Balic, Marija4 aut |
700 | 1 | a Park, Haeseong4 aut |
700 | 1 | a Prat, Aleix4 aut |
700 | 1 | a Isaacs, Claudine4 aut |
700 | 1 | a Bajetta, Emilio4 aut |
700 | 1 | a Balko, Justin M.4 aut |
700 | 1 | a Bellet-Ezquerra, Merixtell4 aut |
700 | 1 | a Bliss, Judith4 aut |
700 | 1 | a Burstein, Harold4 aut |
700 | 1 | a Cardoso, Fatima4 aut |
700 | 1 | a Fohler, Hannes4 aut |
700 | 1 | a Foukakis, Theodorosu Karolinska Institutet4 aut |
700 | 1 | a Gelmon, Karen A.4 aut |
700 | 1 | a Goetz, Matthew4 aut |
700 | 1 | a Haddad, Tufia C.4 aut |
700 | 1 | a Iwata, Hiroji4 aut |
700 | 1 | a Jassem, Jacek4 aut |
700 | 1 | a Lee, Soo-Chin4 aut |
700 | 1 | a Linderholm, Barbro,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xlibar |
700 | 1 | a Los, Maartje4 aut |
700 | 1 | a Mamounas, Eleftherios P.4 aut |
700 | 1 | a Miller, Kathy D.4 aut |
700 | 1 | a Morris, Patrick G.4 aut |
700 | 1 | a Munzone, Elisabetta4 aut |
700 | 1 | a Gal-Yam, Einav Nili4 aut |
700 | 1 | a Ring, Alistair4 aut |
700 | 1 | a Shepherd, Lois4 aut |
700 | 1 | a Singer, Christian4 aut |
700 | 1 | a Thomssen, Christoph4 aut |
700 | 1 | a Tseng, Ling-Ming4 aut |
700 | 1 | a Valagussa, Pinuccia4 aut |
700 | 1 | a Winer, Eric P.4 aut |
700 | 1 | a Wolff, Antonio C.4 aut |
700 | 1 | a Zoppoli, Gabriele4 aut |
700 | 1 | a Machacek-Link, Jana4 aut |
700 | 1 | a Schurmans, Celine4 aut |
700 | 1 | a Huang, Xin4 aut |
700 | 1 | a Gauthier, Eric4 aut |
700 | 1 | a Fesl, Christian4 aut |
700 | 1 | a Dueck, Amylou C.4 aut |
700 | 1 | a DeMichele, Angela4 aut |
700 | 1 | a Gnant, Michael4 aut |
710 | 2 | a Karolinska Institutetb Institutionen för kliniska vetenskaper, Avdelningen för onkologi4 org |
773 | 0 | t JOURNAL OF CLINICAL ONCOLOGYg 41:33q 41:33x 0732-183Xx 1527-7755 |
856 | 4 8 | u https://gup.ub.gu.se/publication/335561 |
856 | 4 8 | u https://doi.org/10.1200/JCO.23.00126 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:237556775 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:154966939 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy